DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/g525xq/multiple) has announced the addition of Decision Resources, Inc's new report "Multiple Sclerosis (Event Driven)" to their offering.

The market for disease-modifying multiple sclerosis (MS) therapies is poised to undergo a dramatic transformation as a suite of new and promising emerging therapies enter the market over the next five years, including the first, and much-anticipated, orally delivered products. Novel therapies will drive growth of the MS market through 2015, but the gains will be constrained by a conservative prescriber base and lingering favoritism for time-tested current agents, at least over the near term, coupled with forecasted generics competition. All new agents are expected to be approved to treat relapsing forms of MS; ample opportunity will remain for therapies to treat the underserved population of patients who suffer progressive forms of the disease.

Key Topics Covered:

Executive Summary

What are the key parameters of the multiple sclerosis market?

What factors are driving the market for multiple sclerosis therapies?

What factors are constraining the market for multiple sclerosis therapies?

What are the drug development activities of note in multiple sclerosis?

What do the experts say?

Read more:
Research and Markets: Multiple Sclerosis (Event Driven)